Boehringer Ingelheim Pharma GmbH & Co. KG has described cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoinflammatory interferonopathy, idiopathic pulmonary fibrosis, cirrhosis, metabolic dysfunction-associated steatohepatitis (MASH), interstitial lung diseases, systemic scleroderma (systemic sclerosis) and systemic lupus erythematosus.

Schrodinger Inc. has divulged EGFR (HER1; erbB1) mutant inhibitors reported to be useful for the treatment of cancer.

Researchers at Dana Farber Cancer Institute Inc. and Stanford University have identified RAF proto-oncogene serine/threonine-protein kinase (RAF1; cRaf) inhibitors reported to be useful for the treatment of cancer.

Eli Lilly & Co. has synthesized relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of pulmonary hypertension, chronic obstructive pulmonary disease, acute kidney disease, chronic kidney disease, diabetic nephropathy and cardiovascular disorders, among others.

Kymera Therapeutics Inc. has disclosed signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, cardiovascular disorders, viral infections, neurodegeneration, and autoimmune, metabolic and liver diseases, among others.

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson’s disease, among others.

Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.

Blossomhill Therapeutics Inc. has identified macrocyclic compounds reported to be useful for the treatment of cancer.

Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized molecular glue degraders comprising cereblon (CRBN) binding agents and protein degradation moieties reported to be useful for the treatment of cancer, infections, autoimmune diseases, anemia, transplant rejection, diabetes, cardiovascular disorders and inflammatory disorders, among others.

Blueprint Medicines Corp. has disclosed PROTAC compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful for the treatment of cancer.